Entero Therapeutics Beheer
Beheer criteriumcontroles 2/4
Entero Therapeutics' CEO is James Sapirstein, appointed in Oct 2019, has a tenure of 5.08 years. total yearly compensation is $1.25M, comprised of 41.2% salary and 58.8% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth $24.64K. The average tenure of the management team and the board of directors is 3.8 years and 5.1 years respectively.
Belangrijke informatie
James Sapirstein
Algemeen directeur
US$1.2m
Totale compensatie
Percentage CEO-salaris | 41.2% |
Dienstverband CEO | 5.1yrs |
Eigendom CEO | 1.1% |
Management gemiddelde ambtstermijn | 3.8yrs |
Gemiddelde ambtstermijn bestuur | 5.1yrs |
Recente managementupdates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$10m |
Mar 31 2024 | n/a | n/a | -US$6m |
Dec 31 2023 | US$1m | US$514k | -US$16m |
Sep 30 2023 | n/a | n/a | -US$16m |
Jun 30 2023 | n/a | n/a | -US$8m |
Mar 31 2023 | n/a | n/a | -US$9m |
Dec 31 2022 | US$742k | US$480k | -US$15m |
Sep 30 2022 | n/a | n/a | -US$22m |
Jun 30 2022 | n/a | n/a | -US$57m |
Mar 31 2022 | n/a | n/a | -US$65m |
Dec 31 2021 | US$1m | US$480k | -US$85m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$74m |
Mar 31 2021 | n/a | n/a | -US$66m |
Dec 31 2020 | US$1m | US$463k | -US$42m |
Sep 30 2020 | n/a | n/a | -US$25m |
Jun 30 2020 | n/a | n/a | -US$15m |
Mar 31 2020 | n/a | n/a | -US$16m |
Dec 31 2019 | US$677k | US$102k | -US$15m |
Compensatie versus markt: James's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: James's compensation has increased whilst the company is unprofitable.
CEO
James Sapirstein (63 yo)
5.1yrs
Tenure
US$1,245,766
Compensatie
Mr. James R. Sapirstein, R.Ph. M.B.A. has been an Independent Director of ZyVersa Therapeutics, Inc. since January 2023. He served as Interim Chief Executive Officer at Marizyme, Inc. since March 19, 2021...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Chairman | 5.1yrs | US$1.25m | 1.1% $ 24.6k | |
Chief Financial Officer | 2.7yrs | US$810.56k | 0.55% $ 12.4k | |
Vice President of Regulatory Affairs | 2.8yrs | geen gegevens | geen gegevens | |
Senior Vice President of Corporate Development | 4.8yrs | geen gegevens | geen gegevens | |
Senior VP for Research & Development | no data | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: ENTO's management team is considered experienced (3.8 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Chairman | 5.1yrs | US$1.25m | 1.1% $ 24.6k | |
Independent Director | 9.2yrs | US$146.02k | 0.000090% $ 2.0 | |
Director | less than a year | geen gegevens | 0.47% $ 10.6k | |
Lead Independent Director | 9.5yrs | US$177.52k | 0.00031% $ 6.9 | |
Director | less than a year | geen gegevens | geen gegevens |
5.1yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: ENTO's board of directors are considered experienced (5.1 years average tenure).